April is shaping up as a very busy month for Bay Area life science companies, at least as it concerns those hoping to enter the public markets. Two of them are set to go public this week through initial public offerings, and several more made plans to head in that direction, filing their IPO paperwork.
There have been quite a few appealing Initial Public Offerings (IPOs) available on the so far this year. Here are some upcoming IPOs that investors should be watching out for. (NASDAQ: Zymergen ZY) is a science & material innovation company that partners with nature to strive to create the products of tomorrow.
Editor's note: Interested in following biopharma's fast-paced IPO market? You can bookmark our IPO Tracker here. It was another busy week in the biotech IPO market as the second quarter continues to churn out significant investment into the sector. Recursion led the way with a $436 million raise on Friday,
MarketQuest.biz has added new key research report titled Global Medical AI Data Analysis Market 2020 by Company, Regions, Type and Application, Forecast to 2026 covering the industry market scenario. The study covers key fundamentals of the industry market.
Josh Ravich, Ingenuity Mars Helicopter Mechanical Engineering Lead, joined Yahoo Finance Live to discuss the helicopter's historic first flight
Eight IPOs are scheduled to raise a total of $3.0 billion in the week ahead, led by software maker UiPath (PATH).
Eight IPOs are scheduled to raise a total of $3. - Renaissance Capital
NEW YORK - The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. Week of April 19 Agiliti - Minneapolis, 26.3 million shares, priced $18-$20, managed by BofA Securities/Goldman Sachs. Proposed NYSE symbol AGTI.
The week ended with a bang for Bay Area companies, at least when it comes to raising money. Fifteen locals startups raised a total of nearly $2 billion in venture funding, including one that pulled added $750 million to an already gargantuan $2 billion round.
Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American Association of Cancer Research's annual meeting provided a platform for oncology-focused biopharma companies to present data from their clinical programs. A negative headline on COVID-19 vaccine, however, marred the week.
Zymergen, a synthetic biology company, has set the price range for its IPO. The Emeryville, Calif.-based company intends to sell 13.6 million shares at between $28 and $31 apiece. At the top of that range, Zymergen would raise $421.6 million and fetch a valuation of $2.96 billion.
NEW YORK (AP) - The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. Agiliti - Minneapolis, 26.3 million shares, priced $18-$20, managed by BofA Securities/Goldman Sachs. Proposed NYSE symbol AGTI. Business: Provides medical equipment management, rental and maintenance services.
After a one-year hiatus induced by the pandemic, Touch Taiwan will stage a strong comeback online April 19-28, with an instant messaging function available to help overseas buyers address travel restrictions amid the pandemic and continue exchanges with Taiwan’s top suppliers to create business opportunities.
The Function Driven Metagenomics market is expected to grow at a CAGR of 9.7% and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report.
The Sequencing Driven Metagenomics Market is expected to grow at a CAGR of 9.1% and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020. The factors leading to this extraordinary growth is attributed various market dynamics discussed in the report Our experts have examined the market from a 360 degree perspective thereby producing a report which is definitely going to impact your business decisions.
The eight-year-old company has hired nearly 800 people, raised more than $870 million and plans to move into one of the East Bay's most iconic spaces as it rolls out an atypical range of products faster, cheaper and in a more environmentally safe way.
EMERYVILLE, Calif., April 13, 2021 /PRNewswire/ -- Leading biofacturing company has named Jay Flatley as the Chairman of the Board of Directors, effective immediately. Jay has served as lead Independent Director on Zymergen's board since late 2019. "Over the last 8 years, we've built a powerful biofacturing platform and excellent customer relationships in our key verticals," said Zymergen CEO, Josh Hoffman.
Metagenomics examines the structure and functional potential of microbial communities in their native habitats through the direct isolation and analysis of community DNA. Metagenomics is a molecular tool used to analyse DNA acquired from environmental samples, in order to study the community of microorganisms present, without the necessity of obtaining pure cultures.
Home / Market News / : This robot-run fund with a history of predicting Tesla price moves has just made these stock picks An exchange-traded fund driven by artificial intelligence has correctly predicted Tesla price movements, and recently shared its most recent portfolio additions and subtractions with MarketWatch.
Jack in the Box Inc. disclosed Wednesday that it will be "separating" from Andrew Martin, who has been the fastfood chain's chief information officer since November 2016, effective May 7. The company did not provide details surrounding the separation.